Radiosensitizing nucleosides

Journal of the National Cancer Institute

Volumn 88, Issue 17, 1996, Pages 1193-1203

  McGinn, Cornelius J ^a   Shewach, Donna S ^b   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; HYDROXYUREA; RADIOSENSITIZING AGENT; THYMIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; RADIOSENSITIZATION; REVIEW;

EID: 0029761745     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.17.1193     Document Type: Review

References (107)

1. Pu AT, Robertson JM, Lawrence TS. Current status of radiation sensitization by fluoropyrimidines. Oncology 1995;9:707-14.
2. Breedis C, Young C. The blood supply of neoplasm in the liver. Am J Pathol 1954;30:969-74.
3. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38(11 Pt 1):3784-92.
4. Meta-Analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8.
5. Robertson JM, Kessler ML, Lawrence TS. Clinical results of three-dimensional conformal irradiation. J Natl Cancer Inst 1994;86:968-74.
6. Robertson JM, Lawrence TS, Andrews JC, Walker S, Kessler ML, Ensminger WD. Long term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys. In press.
7. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-64.
8. Greenhalgh DA, Parish JH. Effects of 5-fluorouracil on cytotoxicity and RNA metabolism in human colonic carcinoma cells. Cancer Chemother Pharmacol 1989;25:37-44.
9. Herrick D, Kufe DW. Lethality associated with incorporation of 5-fluorouracil into preribosomal RNA. Mol Pharmacol 1984;26:134-40.
10. McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol 1992;19:21-8.
11. Lawrence TS, Maybaum J, Ensminger WD. Infusional fluoropyrimidines as radiation sensitizers: clinical implications of laboratory findings. Infusional Chemotherapy 1994;4:120-3.
12. Bruso CE, Shewach DS, Lawrence TS. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1990;19:1411-7.
13. Heimburger DK, Shewach DS, Lawrence TS. The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1991;21:983-7.
14. Davis MA, Tang HY, Maybaum J, Lawrence TS. Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int J Radiat Biol 1995;67:509-17.
15. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994;29:519-23.
16. Lawrence TS, Maybaum J. Fluoropyrimidines as radiation sensitizers. Semin Radiat Oncol 1993;3:20-8.
17. Byfield JE, Calabro-Jones P, Klisak LL, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x rays. Int J Radiat Oncol Biol Phys 1982;8:1923-33.
18. Byfield JE. Useful interactions between 5-fluorouracil and radiation in man: 5-fluorouracil as a radiosensitizer. In: Hill BT, Bellamy AS, editors. Antitumor drug-radiation interactions. Boca Raton (FL): CRC Press, 1990:87-105.
19. Miller EM, Kinsella TJ. Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization. Cancer Res 1992;52:1687-94.
20. McGinn CJ, Miller EM, Lindstrom MJ, Kunugi KA, Johnston PG, Kinsella TJ. The role of cell cycle redistribution in radiosensitization: implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int J Radiat Oncol Biol Phys 1994;30:851-9.
21. Sinclair WK. Cyclic x-ray responses in mammalian cells in vitro. Radiat Res 1968;33:620-43.
22. Terasima T, Tolmach LJ. Variations in several responses of HeLa cells to X-irradiation during the division cycle. Biophys J 1963;3:11-33.
23. Lawrence TS, Davis MA, Tang HY, Maybaum J. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S-phase progression. Int J Radiat Biol. In press.
24. Lawrence TS, Davis MA, Looney TL. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res 1996;56:2303-6.
25. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents [published erratum appears in Oncogene 1993;8:2605]. Oncogene 1993;8:307-18.
26. Tishler RB, Calderwood SK, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993;53(10 Suppl): 2212-6.
27. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
28. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993;53:4164-8.
29. Brachman DG, Becken M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines [see comment citations in Medline]. Cancer Res 1993;53:3667-9.
30. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiationsensitive and -resistant human squamous carcinoma cells. Cancer Res 1992;52:6390-3.
31. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 1995;33:781-96.
32. Jansson T, Inganas M, Sjogren S, Norberg T, Lindgren A, Holmberg L, et al. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 1995;13:2745-51.
33. Epstein AH, Lebovics RS, Goffman T, Teague D, Fuetsch ES, Glatstein E, et al. Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J Natl Cancer Inst 1994; 86:1775-80.
34. Levin VA, Prados MD, Wara WM, Davis RL, Gutin PH, Phillips TL, et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995;32:75-83.
35. Greenberg HS, Chandler WF, Diaz RF, Ensminger WD, Junck L, Page MA, et al. Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas. J Neurosurg 1988;69:500-5.
36. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, et al. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1994;30:583-90.
37. Phillips TL, Levin VA, Ahn DK, Gutin PH, Davis RL, Wilson CB, et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study [see comment citations in Medline]. Int J Radiat Oncol Biol Phys 1991;21:709-14.
38. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg IJ. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 1995;33:339-48.
39. Goffman T, Tochner Z, Glatstein E. Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation. Cancer 1991;67:572-6.
40. Robertson JM, Sondak VK, Weiss SA, Sussman JJ, Chang AE, Lawrence TS. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 1995;31:87-92.
41. Chang AE, Collins JM, Speth PA, Smith R, Rowland JB, Walton L, et al. A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases. J Clin Oncol 1989;7:662-8.
42. Robertson JR, Johnston CM, Eisbruch A, Reynolds K, Roberts J, Lawrence TS. A phase I/II study of bromodeoxyuridine (BrdU) and radiation therapy (RT) for locally advanced cervix cancer. Proc ASCO 1995; 14:201.
43. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321-4.
44. Zimbrick JD, Ward JF, Myers LS Jr. Studies on the chemical basis of cellular radiosensitization by 5-bromouracil substitution in DNA. II. Pulse-and steady state radiolysis of bromouracil-substituted and unsubstituted DNA. Int J Radial Biol Relat Stud Phys Chem Med 1969;16:525-34.
45. Shewach DS, Ellero J, Mancini WR, Ensminger WD. Decrease in TTP pools mediated by 5-bromo-2′-deoxyuridine exposure in a human glioblastoma cell line. Biochem Pharmacol 1992;43:1579-85.
46. Ashman CR, Davidson RL. Bromodeoxyuridine mutagenesis in mammalian cells is related to deoxyribonucleotide pool imbalance. Mol Cell Biol 1981;1:254-60.
47. Ling LL, Ward JF. Radiosensitization of Chinese hamster V79 cells by bromodeoxyuridine substitution of thymidine: enhancement of radiation-induced toxicity and DNA strand break production by monofilar and bifilar substitution. Radiat Res 1990;121:76-83.
48. Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat Res 1992;131:81-9.
49. Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine. Radiat Res 1992;131:90-7.
50. Iliakis G, Kurtzman S. Mechanism of radiosensitization by halogenated pyrimidines: bromodeoxyuridine and alpha-arabinofuranosyladenine affect similar subsets of radiation-induced potentially lethal lesions in plateau-phase Chinese hamster ovary cells. Radiat Res 1991;127:45-51.
51. Iliakis G, Kurtzman S, Pantelias G, Okayasu R. Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing, Radiat Res 1989;119:286-304.
52. Lawrence TS, Davis MA, Normolle DP. Effect of bromodeoxyuridine on radiation-induced DNA damage and repair based on DNA fragment size using pulsed-field gel electrophoresis. Radiat Res 1995;144:282-7.
53. Kinsella TJ, Dobson PP, Mitchell JB, Fornace AJ Jr. Enhancement of x ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 1987;13:733-9.
54. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat Res 1990;123:192-8.
55. Speth PA, Kinsella TJ, Chang AE, Klecker RW, Belanger K, Collins JM. Selective incorporation of iododeoxyuridine in DNA of hepatic metastases versus normal human liver. Clin Pharmacol Ther 1988;44:369-75.
56. Knol JA, Walker SC, Robertson JM, Yang Z, DeRemer S, Stetson PL. et al. Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Res 1995;55:3687-91.
57. Cook JA, Glass J, Lebovics R, Bobo H, Pass H, DeLaney TF, et al. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine. Cancer Res 1992;52:719-25.
58. Russo A, DeGraff W, Kinsella TJ, Gamson J, Glatstein E, Mitchell JB. Potentiation of chemotherapy cytotoxicity following iododeoxyuridine incorporation in Chinese hamster cells. Int J Radiat Oncol Biol Phys 1986; 12:1371-4.
59. Ackland SP, Schilsky RL, Beckett MA, Weichselbaum RR. Synergistic cytotoxicity and DNA strand break formation by bromodeoxyuridine and bleomycin in human tumor cells. Cancer Res 1988;48:4244-9.
60. Chi KH, Kunugi KA, Kinsella TJ. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells. Cancer Res 1994;54:2701-6.
61. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469-75.
62. Lawrence TS, Davis MA, Stetson PL, Maybaum J, Ensminger WD. Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo. Cancer Res 1994;54:2964-8.
63. Sondak VK, Stetson PL, McKeever PE, Chang AE, Lawrence TS. IUdR incorporation and washout in normal human tissues after iv infusion. Proc Am Assoc Cancer Res 1992;33:A2985.
64. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19(3 Suppl 9):1-10.
65. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19(3 Suppl 9):11-9.
66. Lerner HJ. Concomitant hydroxyurea and irradiation. Clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania hospital. Am J Surg 1977;134:505-9.
67. Piver MS, Barlow JJ, Vongtama V, Blumenson L. Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. Am J Obstet Gynecol 1977;129:379-83.
68. Vokes EE, Stupp R, Haraf D, Moran W, Malone D, Wenig B, et al. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol 1995;22:47-52.
69. Piver MS, Vongtama V, Emrich LJ. Hydroxyurea plus pelvic radiation versus placebo plus pelvic radiation in surgically staged stage IIIB cervical cancer. J Surg Oncol 1987;35:129-34.
70. Piver MS, Khalil M, Emrich LJ. Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIB cervical cancer. J Surg Oncol 1989;42:120-5.
71. Stehman FB, Bundy BN, Thomas G, Keys HM, d'Ablaing G 3d, Fowlder WC Jr, et al. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol 1993;11:1523-8.
72. Sinclair WK. Hydroxyurea revisited: a decade of clinical effects studies. Int J Radiat Oncol Biol Phys 1981;7:631-7.
73. Kuo ML, Kinsella TJ. Enhancement of radiosensitivity by pre-irradiation and post-irradiation exposure to hydroxyurea in a human cervical carcinoma cell line, Caski. Proc Am Assoc Cancer Res 1994;35:A3685.
74. Kuo ML, Kunugi KA, Lindstrom MJ, Kinsella TJ. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Res 1995;55:2800-5.
75. Lassmann G, Thelander L, Graslund A. EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea. Biochem Biophys Res Commun 1992;188:879-87.
76. Elledge SJ, Zhou Z, Allen JB, Navas TA. DNA damage and cell cycle regulation of ribonucleotide reductase. Bioessays 1993;15:333-9.
77. Plucinski TM, Fager RS, Reddy GP. Allosteric interaction of components of the replitase complex is responsible for enzyme cross-inhibition. Mol Pharmacol 1990;38:114-20.
78. Stubbe J. Ribonucleotide reductases: amazing and confusing. J Biol Chem 1990;265:5329-32.
79. Moran RG, Danenberg PV, Heidelberger C. Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem Pharmacol 1982;31:2929-35.
80. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994;12:1527-31.
81. Moore M, Andersen J, Burris H, Tarassoff P, Green M, Casper E, et al. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 1995;14:A473.
82. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6.
83. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40.
84. Catimel G, Vermerken JB, Clavel M, de Mulder P, Judson I, Sessa C, et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:543-7.
85. Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J, et al. Difluorodeoxycytidine (GEMCITABINE): a phase II study in patients with advanced breast cancer. Proc ASCO 1993;12:A57.
86. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparision of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988;48:4024-31.
87. Shewach DS, Reynolds KK, Hertel L. Nucleotide specificity of human deoxycytidine kinase. Mol Pharmacol 1992;42:518-24.
88. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,-2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-7.
89. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995;36:181-8.
90. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-72.
91. Schy WE, Hertel LW, Kroin JS, Bloom LB, Goodman MF, Richardson FC. Effect of a template-located 2′,2′-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3′→5′exonuclease-) fragment. Cancer Res 1993;53:4582-7.
92. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533-9.
93. Rockwell S, Grindey GB. Effect of 2′,2′-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res 1992;4: 151-5.
94. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-23.
95. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-72.
96. Iliakis G, Pantelias G, Okayasu R, Seaner R. Comparative studies on repair inhibition by araA, araC and aphidicolin of radiation induced DNA and chromosome damage in rodent cells: comparison with fixation of PLD. Int J Radiat Oncol Biol Phys 1989;16:1261-5.
97. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol 1993;20(5 Suppl 7):13-20.
98. Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993;20(5 Suppl 7):2-12.
99. Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides. Mutat Res 1989;210:291-301.
100. Kim JH, Alfieri AA, Kim SH, Fuks Z. The potentiation of radiation response on murine tumor by fludarabine phosphate. Cancer Lett 1986; 31:69-76.
101. Gregoire V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 1994;54:468-74.
102. Gregoire V, Van NT, Stephens LC, Brock WA, Milas L, Plunkett W, et al. The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 1994;54:6201-9.
103. Gregoire V, Hunter N, Brock WA, Milas L, Plunkett W, Hittelman WN. Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation. Int J Radiat Oncol Biol Phys 1994; 30:363-71.
104. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, MacDonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-7.
105. Rodriguez R, Miller E, Fowler JF, Kinsella TJ. Continuous infusion of halogenated pyrimidines. Int J Radiat Oncol Biol Phys 1991;20:1380-2.
106. Lawrence TS, Ensminger WD. Invited response to letter by Dr. Rodriguez and colleagues. Int J Radiat Oncol Biol Phys 1991;20:1379-82.
107. Vokes EE, Beckett M, Karrison T, Weichselbaum RR. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology 1992;49:454-60.